<!DOCTYPE html>

<!--
  Created : 1/19/2012 3:54:09 PM
  Author : Tom Coleman
  Copyright : 2011-2011
  By : University of Missippi Medical Center
-->

<html>
<head>
<title> Model </title>
<link rel='stylesheet' type='text/css' href='../../Style.CSS'>
</head>

<body>

<img src='../../SmallTitle.PNG'>
<img src='../XMLLightBlue.png'>
<a href='Docs_Leptin.html'><img src='../../Back.PNG'></a>
<p>
QHP 2008 / Leptin.DOCS<br>
<br>
Created : 27-Mar-09<br>
Last Modified : 27-Mar-09<br>
Author : Tom Coleman<br>
Copyright : 2009<br>
<br>
&lt;structurename&gt; LeptinPool &lt;/structurename&gt;<br>
<br>
&lt;vardoc&gt;<br>
&lt;name&gt; LeptinPool.[Leptin(nG/mL)] &lt;/name&gt;<br>
&lt;topic&gt; Leptin - Overview &lt;/topic&gt;<br>
&lt;topic&gt; Leptin - Physical Units &lt;/topic&gt;<br>
&lt;topic&gt; Leptin - Concentration Units &lt;/topic&gt;<br>
&lt;topic&gt; [Leptin(nG/mL)] - DefinitionLP1 &lt;/topic&gt;<br>
&lt;/vardoc&gt;<br>
<br>
&lt;vardoc&gt;<br>
&lt;name&gt; LeptinPool.Change &lt;/name&gt;<br>
&lt;topic&gt; Change - DefinitionLP2 &lt;/topic&gt;<br>
&lt;seealso&gt; LeptinPool.Gain &lt;/seealso&gt;<br>
&lt;seealso&gt; LeptinPool.Loss &lt;/seealso&gt;<br>
&lt;/vardoc&gt;<br>
<br>
&lt;vardoc&gt;<br>
&lt;name&gt; LeptinPool.Gain &lt;/name&gt;<br>
&lt;topic&gt; Gain - DefinitionLP3 &lt;/topic&gt;<br>
&lt;seealso&gt; LeptinSecretion.Rate &lt;/seealso&gt;<br>
&lt;seealso&gt; LeptinPump.Rate &lt;/seealso&gt;<br>
&lt;/vardoc&gt;<br>
<br>
&lt;vardoc&gt;<br>
&lt;name&gt; LeptinPool.InitialMass &lt;/name&gt;<br>
&lt;topic&gt; InitialMass - DefinitionLP4 &lt;/topic&gt;<br>
&lt;seealso&gt; ECFV.Vol(L) &lt;/seealso&gt;<br>
&lt;seealso&gt; LeptinPool.Target[Leptin(nG/mL)] &lt;/seealso&gt;<br>
&lt;/vardoc&gt;<br>
<br>
&lt;vardoc&gt;<br>
&lt;name&gt; LeptinPool.Loss &lt;/name&gt;<br>
&lt;topic&gt; Loss - DefinitionLP5 &lt;/topic&gt;<br>
&lt;seealso&gt; LeptinClearance.Rate &lt;/seealso&gt;<br>
&lt;/vardoc&gt;<br>
<br>
&lt;vardoc&gt;<br>
&lt;name&gt; LeptinPool.Mass &lt;/name&gt;<br>
&lt;topic&gt; Mass - DefinitionLP6 &lt;/topic&gt;<br>
&lt;seealso&gt; LeptinPool.Change &lt;/seealso&gt;<br>
&lt;seealso&gt; LeptinPool.InitialMass &lt;/seealso&gt;<br>
&lt;/vardoc&gt;<br>
<br>
&lt;vardoc&gt;<br>
&lt;name&gt; LeptinPool.Target[Leptin(nG/mL)] &lt;/name&gt;<br>
&lt;topic&gt; Target[Leptin(nG/mL)] - DefinitionLP7 &lt;/topic&gt;<br>
&lt;/vardoc&gt;<br>
<br>
&lt;topicdoc&gt;<br>
&lt;name&gt; Leptin - Overview &lt;/name&gt;<br>
&lt;label&gt; Overview &lt;/label&gt;<br>
&lt;content&gt;<br>
<br>
Leptin is a 167 - amino acid peptide protein synthesized <br>
predominantly in adipose tissue. It is the product of the <br>
ob gene and its name is derived from the greek word <br>
"leptos" which means thin. Mutation or deletion of the ob <br>
gene leads to obesity. Leptin acts via hypothalamic receptors <br>
to inhibit feeding and increase thermogeneis.<br>
<br>
Reviews<br>
Gautron L, Elmquist JK. Sixteen years and counting:<br>
an update on leptin in energy balance. <br>
J Clin Invest 121: 2087 - 2093, 2011.<br>
<br>
Mantzoros CS, Magkos F, Brinkoetter M, Sienkiewicz E,<br>
Dardeno TA, Kim SY, Hamnvik OP, Koniaris A. <br>
Leptin in human physiology and pathophysiology.<br>
Am J Physiol Endocrinol Metab 301: E567 - E584, 2011.<br>
<br>
Jequier E. Leptin signaling, adiposity, and energy balance.<br>
Ann N.Y. Acad Sci 967: 379 - 388, 2002.<br>
<br>
&lt;/content&gt;<br>
&lt;/topicdoc&gt;<br>
<br>
&lt;topicdoc&gt;<br>
&lt;name&gt; [Leptin(nG/mL)] - DefinitionLP1 &lt;/name&gt;<br>
&lt;label&gt; Definition &lt;/label&gt;<br>
&lt;content&gt;<br>
<br>
[Leptin(pG/mL)] is the plasma concentration of Leptin.<br>
<br>
&lt;/content&gt;<br>
&lt;/topicdoc&gt;<br>
<br>
&lt;topicdoc&gt;<br>
&lt;name&gt; Change - DefinitionLP2 &lt;/name&gt;<br>
&lt;label&gt; Definition &lt;/label&gt;<br>
&lt;content&gt;<br>
<br>
Changes in the leptin pool or mass are a function of both<br>
gains and losses in leptin over time. Gains may occur from<br>
increased secretion and from infusion of leptin using the <br>
leptin pump feature of the model. Loss occurs from leptin<br>
clearance from the blood<br>
<br>
<br>
&lt;/content&gt;<br>
&lt;/topicdoc&gt;<br>
<br>
 &lt;topicdoc&gt;<br>
&lt;name&gt; Gain - DefinitionLP3 &lt;/name&gt;<br>
&lt;label&gt; Definition &lt;/label&gt;<br>
&lt;content&gt;<br>
<br>
Gain is defined as positive changes in mass of leptin<br>
and is a function of leptin secretion rate and leptin<br>
from infusion (using the leptin pump feature).<br>
<br>
&lt;/content&gt;<br>
&lt;/topicdoc&gt;<br>
<br>
&lt;topicdoc&gt;<br>
&lt;name&gt; InitialMass - DefinitionLP4 &lt;/name&gt;<br>
&lt;label&gt; Definition &lt;/label&gt;<br>
&lt;content&gt;<br>
<br>
During startup, the model user defines the particular <br>
traits of the HumMod patient. These are gender, body size, <br>
age, muscularity and adiposity. All of these traits <br>
influence body volumes, most notably the extracellular <br>
fluid volume (ECFV). The assumption is made that<br>
while volumes may change with traits, concentrations do <br>
not. At startup,initial volumes,especially ECFV and plasma <br>
volume are calculated. A target concentration is specified <br>
- in this case Target[Leptin(nG/mL)]. <br>
<br>
The initial mass or circulating pool is the Target[Leptin] <br>
multiplied by the initial volume of distribution, in <br>
this case the ECFV.<br>
 <br>
Initial Mass = Target[Leptin(nG/mL)]*ECFV.InitialVol(L)<br>
<br>
&lt;/content&gt;<br>
&lt;/topicdoc&gt;<br>
<br>
&lt;topicdoc&gt;<br>
&lt;name&gt; Loss - DefinitionLP5 &lt;/name&gt;<br>
&lt;label&gt; Definition &lt;/label&gt;<br>
&lt;content&gt;<br>
<br>
Loss is defined as negative changes in mass of leptin and is <br>
a function of leptin clearance rate.<br>
<br>
&lt;/content&gt;<br>
&lt;/topicdoc&gt;<br>
<br>
&lt;topicdoc&gt;<br>
&lt;name&gt; Mass - DefinitionLP6 &lt;/name&gt;<br>
&lt;label&gt; Definition &lt;/label&gt;<br>
&lt;content&gt;<br>
<br>
The Mass is the calculated amount of Leptin at any given time. <br>
It is a function of the initial mass of Leptin and the change <br>
in Leptin mass over time. <br>
<br>
<br>
&lt;/content&gt;<br>
&lt;/topicdoc&gt;<br>
<br>
&lt;topicdoc&gt;<br>
&lt;name&gt; Target[Leptin(nG/mL)] - DefinitionLP7 &lt;/name&gt;<br>
&lt;label&gt; Definition &lt;/label&gt;<br>
&lt;content&gt;<br>
<br>
Target[Leptin(nG/mL)] is the plasma concentration of Leptin<br>
at startup. <br>
<br>
During startup, the model user defines the particular <br>
traits of the HumMod patient. These are gender, body size, <br>
age, muscularity and adiposity. All of these traits <br>
influence body volumes, most notably the extracellular <br>
fluid volume (ECFV). The assumption is made that<br>
while volumes may change with traits, concentrations do <br>
not. At startup,initial volumes,especially ECFV and plasma <br>
volume are calculated. A target concentration is specified <br>
- in this case Target[Leptin]. <br>
<br>
&lt;/content&gt;<br>
&lt;/topicdoc&gt;<br>
<br>
&lt;topicdoc&gt;<br>
&lt;name&gt; Leptin - Physical Units &lt;/name&gt;<br>
&lt;label&gt; Physical Units &lt;/label&gt;<br>
&lt;content&gt;<br>
<br>
Plasma nG/mL<br>
Mass : uG<br>
Secretion/Clearance Rate: uG/Min<br>
<br>
&lt;/content&gt;<br>
&lt;/topicdoc&gt;<br>
<br>
&lt;topicdoc&gt;<br>
&lt;name&gt; Leptin - Concentration Units &lt;/name&gt;<br>
&lt;label&gt; Concentration Units &lt;/label&gt;<br>
&lt;content&gt;<br>
<br>
Plasma leptin levels correlate highly with percentage body <br>
fat, increasing exponentially with increasing body mass<br>
index (BMI). There is a great deal of interindividual <br>
variability in plasma leptin concentration and gender is also<br>
an important factor, with women having markedly higher leptin <br>
concentrations than men for any given degree of fat mass.<br>
<br>
In HumMod, plasma leptin concentartion is 8.0 nG/mL <br>
<br>
Human Data<br>
Reference (1)<br>
Mean (+/- SD) plasma concentrations of leptin were <br>
7.5 +/- 9.3 nG/mL (n = 27) in normal weight subjects and <br>
31.3 +/- 24.1 nG/mL (n = 27) in obese subjects. In this<br>
particular study, men and women were grouped together.<br>
<br>
Considine RV, Sinha MK, Heiman ML, Kriauciunas A,<br>
Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ,<br>
Bauer TL, Caro JF. Serum immunoreactive-leptin<br>
concentrations in normal-weight and obese humans.<br>
N Engl J Med 334; 292 - 295, 1996.<br>
<br>
Reference (2)<br>
Men (n = 19) Leptin levels ranged between 1.8 - 14.4 nG/mL <br>
Women (n = 11)  Leptin levels ranged between 7.2 - 28.9 nG/mL  <br>
Fat Mass = 14 -16 Kg<br>
<br>
Saad MF, Damani RL, Gingerich RL, Riad-Gabreil MG, <br>
Khan A, Boyadijan R, Jinagouda SD, el-Tawil K, Rude RK, <br>
Kamdr V. Sexual dimorphism in plasma leptin concentration.<br>
J Cil Endocrinol Metab 82: 579 - 584, 1997.<br>
<br>
Reference (3)<br>
Mean (+/- SD) plasma concentrations of leptin were<br>
(n = 56) 8.4 +/- 0.9 nG/mL; BMI = 23.8 +/- 0.4 kg/m^2<br>
(Range in BMI 18.4 - 30.8). No indication as to sex <br>
of control subjects.<br>
<br>
Stenvinkel P, Heimburger O, Lonnqvist F. Serum leptin<br>
concentrations correlate to plasma insulin concentrations<br>
independent of body fat content in chronic renal failure.<br>
Nephr Dial Transplant 12: 1321 - 1325, 1997.<br>
<br>
Reference (4)<br>
Men (n = 20) 1.6 +/- 1.1 nG/mL with a BMI of less than 25<br>
    (n = 14) 3.8 +/- 2.0 nG/mL with a BMI of 25 - 30<br>
    (n = 9)  7.5 +/- 6.4 nG/mL with a BMI greater than 30<br>
Women (n = 4) 11.1 +/- 8.1 nG/mL with a BMI less than 25<br>
	(n = 8) 18.8 +/- 7.6 nG/mL with a BMI 25 - 30<br>
	(n = 8) 36.7 +/- 17.5 nG/mL with a BMI greater than 30<br>
<br>
Wong SL, DePaoli AM, Lee JH, Mantzoros CS. Leptin<br>
hormonal kinetics in the fed state: effects of adipocity, <br>
age, and gender on endogenous leptin production and clearance.<br>
J Clin Endocrinol Metab 89: 2672 - 2677, 2004.<br>
<br>
Reference (5)<br>
Women (n = 20) 5.7 +/- 0.8 nG/ml; BMI = 19.4 +/- 0.5 kg/m^2<br>
Women (n = 8) 17.4 +/- 2.2 nG/mL; BMI = 29.5 +/- 2.0 kg/m^2<br>
<br>
Escobar-Morreale HF, Serrano-Gotarredona J, Varela C,<br>
Garcia-Robles R, Sancho JM. Circulating leptin concentrations<br>
in women with hirsutism. <br>
Fertility and Sterility 68: 898 - 906, 1997. <br>
<br>
Reference (6)<br>
(n = 5) 5.4 nG/mL +/- 0.9 nG/mL; BMI = 22.1 +/- 0.9 kg/m^2<br>
(n = 5) 5.7 +/- 1.2 nG/mL; BMI = 24.7 +/- 1.1 kg/m^2<br>
(n = 3) 35.0 +/- 6.6 nG/mL; BMI = 50.3 +/- 2.0 kg/m^2<br>
<br>
Ozata M, Dieguez C, Casanueva FF. The inhibition of growth<br>
hormone secretion presented in obesity is not mediated by<br>
the high leptin levels: a study in human leptin deficiency<br>
patients. J Clin Endocrinol Metab 88: 312 - 316, 1988.<br>
<br>
Dog Data<br>
(n = 36) 2.7 +/- 0.3 nG/mL - no figures for body fat content<br>
but these dogs had an optimal BCS of 3 ( BCS is a widely used<br>
index of nutritional condition and obesity in animals). <br>
(n = 5) 2.4 +/- 1.2 nG/mL; 15.7 +/- 2.2 % body fat.<br>
(n = 5) 4.9 nG/mL; 31.8 +/- 4.1 % body fat.<br>
 <br>
Ishioka K, Soliman MM, Sagawa M, Nakadomo F, Shibata H, Honjoh T,<br>
Hashimoto A, Kitamura H, Kimura K, Saito M. Experimental and<br>
clinical studies on plasma leptin in obese dogs.<br>
J Vet Med Sci 64: 349 - 353, 2002.<br>
<br>
Rat Data<br>
(n = 5) 1.2 +/- 0.4 nG/mL<br>
(n = 5) 0.9 +/- 0.1 nG/mL<br>
 <br>
Shek EW, Brands MW, Hall JE. Chronic leptin infusion increases <br>
arterial pressure. Hypertension 31: 409 - 414, 1998.<br>
<br>
&lt;/content&gt;<br>
&lt;/topicdoc&gt;<br>
<br>
<br>
<br>
End

<p><img src='../../Footer.PNG'>

</body>
</html>
